The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Participants or their legal representative must sign written inform consent form (ICF)
Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described.
Participants who are unable to understand all implications of study participation.
Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab.
Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.